>> Take a gander at the following testimonial below and explain to me why BIEL and its products aren't the talk and toast of the Pain-Management World (yes! Globally!). Why is it such an apparent struggle for BIEL to get going, in earnest? Hmm! A mystery wrapped in an enigma; it seems.
GLTA!!
Testimonials
“I use RecoveryRx™ on every facial procedure. It reduces my patients bruising and swelling by 50% following Blepharoplasty, Face Lifts, and Rhinoplasty. As a result of RecoveryRx, two weeks of standard surgical recovery has been reduced to 5-7 days.”
Laurie Casas MD, FACS
Northwestern University
Feinberg School of Medicine <<
I’ll give this a shot DL. I do believe we have a disruptive technology given its amazing efficacy, price point, no side effects, and ease of use (portability). One could easily view that as the ”talk and toast of the Pain Management World” especially given the increasing partnerships and product adoption by OEM’s.
For others, the “enigma” remains when looking at the PPS and Daily Volume. That is their metric for “talk and toast”. People want to make money when investing. They want a steady and appreciably rising PPS and Daily Volume and will tolerate the usual range-bound ups and downs, but expect a move to the next leg up within a reasonable period of time.
There are many parts to product/company successes that many savvy investors consider before investing. No need to list them all. They’re important to varying degrees for measuring that “talk and toast” depending on who is doing the DD, and thus a decision to invest or not.
We could talk all day night, back and forth and to no end, about why we are, or are not, the “talk and toast of the Pain Management World”. It’s a matter of perspective and depends on what metric(s) one uses to answer that question.
For enough, the enigma can’t be reconciled in their minds given the last year’s drop in PPS as contrasted with ever increasing OEM’s/partnerships and yet persistent low PPS and Daily low Volume.
Not all got in at .0003 -.0006 and are in the green. Bottom line is that current investors need those saddled with the “enigma” concerns to invest to move this thing up from here. The “newbies”. They’re not appreciably buying as evidenced by PPS and DV.
All imo, and GLTA
